Form 4: Chimerix Officer Sells Shares to Cover Tax Obligations

Allen S. Melemed, Chief Medical Officer of Chimerix, Inc., sold 3,065 shares of common stock to cover tax liabilities incurred upon the vesting of restricted stock units.

Summary

• On February 13, 2025, Allen S. Melemed, the Chief Medical Officer of Chimerix, Inc., sold 3,065 shares of the company's common stock.
• The shares were sold at a weighted average price of $4.502 per share, with individual transactions ranging from $4.50 to $4.51.
• The sale was executed to cover the reporting person's tax liability resulting from the vesting of restricted stock units granted on February 1, 2024.
• The sales were made pursuant to an automatic sell-to-cover arrangement adopted under Rule 10b5-1.
• Following the transaction, Melemed directly owns 152,875 shares of Chimerix common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing relates to a routine transaction for tax purposes and doesn't indicate a change in the officer's outlook for the company.

Industry Context

This is a routine Form 4 filing, reflecting an insider transaction to cover tax obligations. Such transactions are common and generally don't indicate a change in the officer's long-term outlook for the company.

Comparison to Industry Standards

• Insider sales to cover tax obligations are a common practice across publicly traded companies.
• The use of Rule 10b5-1 trading plans is a standard method to avoid accusations of trading on inside information, aligning with best practices in corporate governance.
• Comparable companies in the biotechnology sector, such as Gilead Sciences or Amgen, often see similar filings from their executives.

Key Dates